Fox Business
Expand
Browse All Video
Watch Live

You're watching...

Boost Your Portfolio with Pharma?

Details

  • Description

    FBN’s Charles Payne on why investors should consider The Medicines Company for their portfolios.

  • Duration 2:04
  • Date

Clips

Also in this playlist...

Markets Now

Auto-advance: ON

Auto-advance
View All

Transcript

This transcript is automatically generated

-- is down and makes money with jobs pain in this hour we are taking a look at a pharmaceutical company in the green today -- good Charles has -- down on the Dow but they're points.

Markets not looking too good well suitable Isabel while critically about that this the company -- The Medicines Co.

and -- that relatively well known.

-- stock became she briefly they beat the street by 50% 47% forty -- and then they had a missed.

Stock pullback they've got one they've got three strong products already out there when I'm a -- intrigued by is their product pipeline.

Got a lot of anti platelet agents including -- -- ten were -- That was just review by the University of Munich tremendous review patients -- on a -- having a cardiac surgery.

You know we've got to get all up Plavix that are sort of counteract that.

I think of this gets approved by the way three products in phase three which is obviously you know the step -- -- new drug of up application then.

And then you go to the market of one of these gets approved I think the stockpiles and certainly this one gets approved I think it makes a pretty good -- in the meantime.

Even though they -- street the last time they reported.

Operating margins with 11% from seven point 8% technically the stock is on the verge of breaking out here like -- it close about 22.

I think it has room to 26 I would suggest twenty anybody in the stock -- looking at it as a stop loss potential.

One he is so it's 22 right now you want to see close of at -- like you are you go.

There again they continue L -- could see the volume build on it I've seen the stock in the past pop.

I have my radar you know not too long ago end I've been waiting for a moment to look at it for -- -- -- long entry.

I just think it's oversold it has a pretty tight trading range that never even heard of dumb medicines company it was a bit of a generic title isn't it.

Mean some big drug -- gonna buy these kind.

I don't know -- did there might be early in the game to say that but certainly you know what a lot of these big drug giants have these big lumbering old products.

That keep coming off for that approval down.

You know what.

Acquisitions a lot better sometime and staffing entire idea might get my act exactly they have cash.

And so what the heck it's a good match.

All right thanks -- -- Leavitt thanks Charles together to get back to those tweaks yes we shed and more.

Load More